Anthony J. Doyle serves as the Chief Financial Officer and Treasurer at BioCryst Pharmaceuticals Inc., a position he has held since joining the company in 2019. With over 25 years of experience in the life sciences industry, Doyle has a proven track record of driving financial growth and operational excellence. Prior to BioCryst, he was the CFO at Spark Therapeutics, where he played a pivotal role in the company's successful IPO and subsequent acquisition by Roche for $4.8 billion. His strategic financial leadership has been instrumental in guiding BioCryst through critical stages of its development, particularly in advancing its portfolio of innovative treatments for rare diseases. At BioCryst, Doyle oversees all financial aspects of the company, including financial planning and analysis, accounting, investor relations, and treasury management. His leadership has been crucial in securing funding and partnerships necessary for the company's growth, such as the recent collaboration with Clearside Biomedical to develop treatments for retinal diseases. Under his guidance, BioCryst has strengthened its financial position, allowing the company to invest in research and development and expand its global reach. Doyle's expertise in financial strategy and his ability to navigate complex markets have solidified his reputation as a key asset to BioCryst's executive team. Before his tenure at Spark Therapeutics, Doyle held various senior financial roles at Shire Pharmaceuticals, where he contributed to the company's growth from a small biotech firm to a global leader in rare disease treatments. His career also includes significant positions at Ernst & Young and KPMG, where he honed his skills in financial auditing and consulting. Doyle holds a Bachelor of Commerce degree from University College Dublin and is a Fellow of the Institute of Chartered Accountants in Ireland. His extensive background and strategic vision continue to drive BioCryst's mission to develop life-changing therapies for patients worldwide.